Catherine Angell Sohn

Catherine Angell Sohn, Pharm.D. is a senior adviser to the Armis Biopharma Board of Directors based on 30 years of US and global experience in health-related sectors, across pharmaceuticals and consumer products, licensing/partnering, M&A, strategy and new product development and commercial launch.

Dr. Sohn is a biopharmaceutical and consumer healthcare executive, adviser and public company Board Director with expertise in strategy, strategic product development, business development/M&A, commercialization of new medicines and vaccines, and public company Board governance. Dr. Sohn is currently chairman of BioEclipse Therapeutics, a privately held, clinical-stage oncology company and is an independent Director on the Board of Directors of Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Rubius Therapeutics (NASDAQ: RUBY), Axcella Health (NASDAQ: AXLA), Landec Corp (NASDAQ: LNDC) and Maze Therapeutics (privately held). Dr. Sohn also particularly enjoys engaging with students as Adjunct Professor at the University of California, San Francisco, her alma mater.

Dr. Sohn was formerly senior vice president, Worldwide Business Development and a member of the global executive committee at GlaxoSmithKline Consumer Healthcare where she led U.S. and global transactions, including the $1.3 billion acquisition and integration of Block Drug and the $566 million acquisition of CNS, Inc. Before that, she was Vice President Worldwide Strategic Product Development for the cardiovascular, pulmonary and metabolic therapeutic areas at SmithKline Beecham Pharmaceuticals, overseeing the global launch of Coreg for congestive heart failure which became a $1 billion indication and responsible for portfolio prioritizations. Earlier in her career, as an entrepreneur within a large company, she started the

U.S. Vaccine Business and led the launch of SB’s first vaccine in the U.S. and helped shape the global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee. Subsequently, she led the US commercialization of the company’s largest CNS product.

From 1999-2005, Dr. Sohn served on the Johns Hopkins Bloomberg School of Public Health’s Advisory Board. Dr. Sohn was recognized as “Distinguished Alumnus of the Year” by UCSF in 2000, was named “Woman of the Year” in 2003 by the Healthcare Businesswomen’s Association, received the Licensing Executive Society’s Frank Barnes Mentoring Award in 2009 and the HBA Euro-Excellence Award in 2012. In 2016, SOHN was recognized as one of the PharmaVoice 100 ‘most inspiring people in the Life Science Industry’. She began her career in the pharmaceutical industry in Medical Affairs at SK&F in 1982 after 4 years as Assistant Professor at The Philadelphia College of Pharmacy.

Dr. Sohn received a Doctor of Pharmacy degree from the University of California, San Francisco, a Certificate of Professional Development from the Wharton School at the University of Pennsylvania, and she is a Board Leadership Fellow of the National Association of Corporate Directors (NACD) and a Certified Licensing Professional (CLP) Emeritus.